However, allogeneic T cell therapy faces significant challenges, including the risk of GvHD due to the alloreactive TCR repertoire of the infused cells, and the potential for rapid rejection mediated by host CD8+ T cells and NK cells (222). This evidence concerns the gene CD8A and graft versus host disease.